Abstract
The complement component 1, q subcomponent binding protein (C1QBP/gC1q-R/p32/HABP1/TAP/YBAP1), is a ubiquitous, multifunctional protein. C1QBP localizes mainly to mitochondria due to its N-terminal mitochondrial localization signal, but it can also be found in different subcellular compartments including the cell surface, nucleus, cytoplasm, and extracellular space. C1QBP has been reported to interact with a variety of proteins that have apparently unrelated functions. C1QBP has also been observed to interact with hyaluronic acid and RNA. These findings suggest that C1QBP has both mitochondrial and extramitochondrial functions. The C1QBP binding sites of many partner proteins are located within basic and intrinsically disordered regions of these molecules, consistent with the hypothesis that C1QBP functions as a molecular chaperone. C1QBP expression is elevated in various types of human cancers, including breast cancer. Moreover, it has been implicated in the development, progression, and metastasis of cancer cells based on loss-of-function and gain-of-function studies using cancer cell lines and xenograft models. Hence C1QBP could be a molecular target in breast cancer therapy. Studies using antibodies, tumor homing peptides such as LyP-1, and small molecules that target C1QBP warrant further investigation as C1QBP is a potential therapeutic target.
Keywords: C1QBP, p32, breast cancer, mitochondria, gC1q-R, LyP-1.
Current Medicinal Chemistry
Title:Role of C1QBP/p32 and its Therapeutic Potential in Breast Carcinoma and other Cancers
Volume: 28 Issue: 25
Author(s): Ken Matsumoto*Boon-Huat Bay
Affiliation:
- Chemical Genomics Research Group, RIKEN Center for Sustainable Resource Science, Saitama 351-0198,Japan
Keywords: C1QBP, p32, breast cancer, mitochondria, gC1q-R, LyP-1.
Abstract: The complement component 1, q subcomponent binding protein (C1QBP/gC1q-R/p32/HABP1/TAP/YBAP1), is a ubiquitous, multifunctional protein. C1QBP localizes mainly to mitochondria due to its N-terminal mitochondrial localization signal, but it can also be found in different subcellular compartments including the cell surface, nucleus, cytoplasm, and extracellular space. C1QBP has been reported to interact with a variety of proteins that have apparently unrelated functions. C1QBP has also been observed to interact with hyaluronic acid and RNA. These findings suggest that C1QBP has both mitochondrial and extramitochondrial functions. The C1QBP binding sites of many partner proteins are located within basic and intrinsically disordered regions of these molecules, consistent with the hypothesis that C1QBP functions as a molecular chaperone. C1QBP expression is elevated in various types of human cancers, including breast cancer. Moreover, it has been implicated in the development, progression, and metastasis of cancer cells based on loss-of-function and gain-of-function studies using cancer cell lines and xenograft models. Hence C1QBP could be a molecular target in breast cancer therapy. Studies using antibodies, tumor homing peptides such as LyP-1, and small molecules that target C1QBP warrant further investigation as C1QBP is a potential therapeutic target.
Export Options
About this article
Cite this article as:
Matsumoto Ken *, Bay Boon-Huat, Role of C1QBP/p32 and its Therapeutic Potential in Breast Carcinoma and other Cancers, Current Medicinal Chemistry 2021; 28 (25) . https://dx.doi.org/10.2174/0929867328666201231124038
DOI https://dx.doi.org/10.2174/0929867328666201231124038 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the Treatment of Chronic Inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Isoform-Selective PI3K Inhibitors for Various Diseases
Current Topics in Medicinal Chemistry Transmission and Immunopathogenesis of FIV in Cats as a Model for HIV
Current HIV Research Sesamol Induces Apoptosis by Altering Expression of Bcl-2 and Bax Proteins and Modifies Skin Tumor Development in Balb/c Mice
Anti-Cancer Agents in Medicinal Chemistry Heterologous Prime-boost Vaccination Using Adenovirus and Albumin Nanoparticles as Carriers for Human Papillomavirus 16 E7 Epitope
Current Pharmaceutical Biotechnology Natural Products as Anticancer Agents
Current Drug Targets Co-delivery of Plasmid DNA and Antisense Oligodeoxyribonucleotide into Human Carcinoma Cells by Cationic Liposomes
Current Pharmaceutical Biotechnology Sildenafil Inhibits the Growth and Epithelial-to-mesenchymal Transition of Cervical Cancer via the TGF-β1/Smad2/3 Pathway
Current Cancer Drug Targets Nanoparticulate Drug Delivery System to Overcome the Limitations of Conventional Curcumin in the Treatment of Various Cancers: A Review
Drug Delivery Letters Potential Interactions between miRNAs and Hypoxia: A New Layer in Cancer Hypoxia
Anti-Cancer Agents in Medicinal Chemistry Immunotherapy for Gastroesophageal Tumors: Is there still Hope for Efficacy?
Current Cancer Drug Targets Oncogene Expression Modulation in Cancer Cell Lines by DNA G-Quadruplex-Interactive Small Molecules
Current Medicinal Chemistry Pleiotropic Effect of Mahanine and Girinimbine Analogs: Anticancer Mechanism and its Therapeutic Versatility
Anti-Cancer Agents in Medicinal Chemistry The Anti-cancer Actions of Vitamin D
Anti-Cancer Agents in Medicinal Chemistry HGF/MET Signaling in Ovarian Cancer
Current Molecular Medicine Gold Complexes for Therapeutic Purposes: an Updated Patent Review (2010-2015)
Current Medicinal Chemistry Approaches to Improve Efficiency of Dendritic Cell-based Therapy of High Grade Gliomas
Current Pharmaceutical Design Medicinal Chemistry of Probimane and MST-16: Comparison of Anticancer Effects Between Bisdioxopiperazines
Medicinal Chemistry Anti-cancer Nitrogen-Containing Heterocyclic Compounds
Current Organic Chemistry Monofunctional Platinum (PtII) Compounds – Shifting the Paradigm in Designing New Pt-based Anticancer Agents
Current Medicinal Chemistry Evaluation of the Radioprotective Effects of Melatonin Against Ionizing Radiation-Induced Muscle Tissue Injury
Current Radiopharmaceuticals